Document is current

Article History

Received: 2 January 2025

Accepted: 17 February 2025

First Online: 7 April 2025

Disclosure

: JZ–global principal investigator in the FOCUS phase 3 study and serves on Delcath Systems Medical Advisory Board. Education and Training grant through Delcath. Has consulting agreements and/or participated on advisory board panels with Merit Medical, Replumune, Merck, Philogen, Castle Biosciences and Menarini Silicon Biosystems. MO–Advisory Board: Delcath, Replimune. Consultant: Immunocore. Steering Committee: Ideaya. Speaker: Immunocore. DE–Consulting fees from Delcath. EG–Institutional funding for conducting the Phase 3 FOCUS study. JH–Consultant: Delcath. ER–Medical University of Graz received payments for conducting the Phase 3 FOCUS study. SO–Advice: Immunocore, Delcath, Janssen. Speakers’ bureau: Immunocore. Honoraria for presentations: MSD, AstraZeneca, Merck; Travel funding: Merck, Pfizer, Ipsen. GB–Clinical trial funding paid to institution from Replimune, Checkmate pharmaceuticals, Philogen, Delcath. Advisory board: BMS. AG–University Hospital Würzburg received institutional payments for conducting the Phase 3 FOCUS study. RD–Consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere and touchIME. AA–Consulting or advisory role: Pierre Fabre, Novartis, Roche, BMS, MSD, Biontech. Speakers’ Bureau: Pierre Fabre, Novartis, Roche, BMS, MSD. Travel, Accommodations, Expenses: BMS, MSD. SF–Liverpool University Hospitals NHS Trust received institutional support for conducting this Phase 3 FOCUS study from the trial sponsor. JS–Advisory boards: Delcath, Replimune and Immunocore. Grant funding: Astra Zeneca and BMS (paid to institution). Travel and conference attendance: MSD, BMS and Replimune. SH - Speakers Honoraria: BMS, MSD, Pierre Fabre, Sanofi, Immunocore. MW–Institutional (University Hospital Southampton) funding for conducting a commercial trial. Personal funding for participation in advisory board for Delcath. JJ–Employee of Delcath.